Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Documenti analoghi

• Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
  di: Foss, Francine, et al.
  Pubblicazione: (2016)
• Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
  di: Foss, Francine, et al.
  Pubblicazione: (2016)
• Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
  di: Foss, Francine, et al.
  Pubblicazione: (2014)
• Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
  di: Coiffier, Bertrand, et al.
  Pubblicazione: (2014)
• Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
  di: Pro, Barbara, et al.
  Pubblicazione: (2016)